Phase Ib/IIa Study of Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Carfilzomib (Primary) ; Lenalidomide (Primary) ; Romidepsin (Primary)
- Indications B cell lymphoma; T cell lymphoma
- Focus Adverse reactions
- 05 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 05 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 12 Dec 2017 Phase II results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology